^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Xcytrin (motexafin gadolinum)

i
Other names: Gd-Tex, GdT2B2, PCI 0120, API-GP3, FP-GP1, Gd-texaphyrin, GdT2B2 MGd
Associations
Company:
AbbVie
Drug class:
Ribonucleotide reductase inhibitor
Associations
3ms
Lutetium texaphyrin: A photocatalyst that triggers pyroptosis via biomolecular photoredox catalysis. (PubMed, Proc Natl Acad Sci U S A)
The first control, gadolinium texaphyrin (MGd), is a weak photocatalyst but generates reactive oxygen species (ROS) efficiently...Even in the presence of a ROS scavenger, treating MDA-MB-231 cells with MLu at concentrations as low as 50 nM still allows for pyroptosis photo-activation. The present findings highlight how biomolecular photoredox catalysis could contribute to pyroptosis activation by mechanisms largely independent of ROS.
Journal
|
CASP3 (Caspase 3) • GSDME (Gasdermin E)
|
Xcytrin (motexafin gadolinum)
7ms
Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy. (PubMed, Nat Commun)
Gadolinium (Gd)-coordinated texaphyrin (Gd-Tex) is a promising radiosensitizer that entered clinical trials, but temporarily fails largely due to insufficient radiosensitization efficacy...In addition to Gd, the versatile Mb@Gd-NTs can also chelate Lu (Mb@Lu/Gd-NTs), enabling SPECT/MRI dual-modality imaging for accurately monitoring drug delivery in real-time. This "one-for-all" nanoplatform with the capability of chelating various trivalent metal ions exhibits broad clinical application prospects in imaging-guided radiosensitization therapy.
Journal
|
MB (Myoglobin)
|
Xcytrin (motexafin gadolinum)
11ms
ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov)
P=N/A, N=440, Active, not recruiting, American College of Radiology Imaging Network | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date
|
Xcytrin (motexafin gadolinum)